CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

The U.S. Food and Drug Administration has granted full approval for Moderna's MRNA.O COVID-19 vaccine, Spikevax, in children ...

The company announced the FDA’s full approval in a statement July 10, noting its COVID-19 vaccine, mRNA-1273, was previously available for pediatric populations under emergency use authorization.

“The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,” said Stéphane Bancel, Chief Executive ...

Moderna (NASDAQ:MRNA) saw its stock rise nearly 5% in premarket trading on Monday following the U.S. Food and Drug Administration’s approval of its next-generation COVID-19 vaccine, mNEXSPIKE ...

Press Releases Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE ACCESS Newswire May 31, 2025 12:31 AM ...

The company announced the FDA’s full approval in a statement on July 10, noting its COVID-19 vaccine, mRNA-1273, was previously available for pediatric populations under emergency use authorization.

The primary efficacy objective in this study was to demonstrate the non-inferior vaccine efficacy against COVID-19 starting 14 days after mNEXSPIKE compared to that after the comparator vaccine ...